Femasys Inc. said the American Medical Association CPT Editorial Panel approved a new, unique Category III CPT code covering the use of FemaSeed for intratubal insemination (ITI). The company said the code is expected to be issued publicly by the AMA with an effective date of Jan. 1, 2027, and described the approval as a step in its U.S. reimbursement strategy intended to support broader clinical adoption, provider utilization and patient access. Femasys also cited results from its pivotal clinical trial (NCT0468847), stating that FemaSeed achieved more than double the pregnancy rates of intrauterine insemination (IUI) in a low male sperm count setting, and said FemaSeed is authorized for use in the U.S., Europe, the UK, Canada and Israel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602230900PRIMZONEFULLFEED9658868) on February 23, 2026, and is solely responsible for the information contained therein.